Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.

Abstract

At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive combined reduced-antigen-content diphtheria-tetanus and acellular pertussis vaccine (dTpa) versus tetanus-diphtheria (Td)+monovalent acellular pertussis (pa) were seroprotected against diphtheria (> or =0.016IU/mL Vero cell assay) and tetanus (> or =0.1IU/mL ELISA assay) in 94.4% and 96.2%, respectively (dTpa), compared with 93.7% and 90.6% (Td+pa). Anti-FHA, anti-PT and anti-PRN antibodies (> or =5EL.U/mL) were maintained in 100%, 89.5% and 95.0% of dTpa versus 100%, 85.5% and 90.6% of pa vaccine recipients. At 5 years post boosting, antibody levels to diphtheria and tetanus are similar amongst adults receiving a dTpa or dT, and pertussis antibodies remain above pre-booster levels in at least 85%.

• Authors: Peter B McIntyre, Margaret A Burgess, Annemarie Egan, Lode Schuerman, Bernard Hoet
• Journal: Vaccine (Vaccine) Vol. 27 Issue 7 Pg. 1062-6 (Feb 11 2009) ISSN: 0264-410X [Print] Netherlands
• PMID: 19095033 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antibodies, Bacterial
• Diphtheria-Tetanus-acellular Pertussis Vaccines

Topics

• Adult
• Aged
• Antibodies, Bacterial (blood)
• Diphtheria-Tetanus-acellular Pertussis Vaccines (immunology)
• Female
• Humans
• Immunization, Secondary (methods)
• Longitudinal Studies
• Male
• Middle Aged
• Neutralization Tests